Calnexin-Dependent Modulation of CFTR Variant Rescue: Insights from Deep Mutational Scanning

Study Background and Research Question

Cystic fibrosis (CF) is a life-limiting genetic disorder predominantly caused by mutations in the CFTR gene, which encodes the cystic fibrosis transmembrane conductance regulator protein. The most common molecular defect arises from the F508del mutation in CFTR, but there are over 1700 reported mutations, many of which produce diverse effects on protein folding, trafficking, and functional expression at the cell surface. While small-molecule correctors (such as VX-661) can partially restore the function of some mutant CFTR proteins, the response to these molecules is highly variable across different CFTR variants. A critical open question in the field remains: what determines whether a given CFTR variant is amenable to rescue by correctors, and how do endogenous quality control mechanisms, such as the ER chaperone calnexin (CANX), shape this response?

Key Innovation from the Reference Study

Tedman et al. (2025, eLife) deliver a comprehensive, quantitative analysis of how calnexin influences the expression and pharmacological rescue of a broad spectrum of clinical CFTR variants. Using deep mutational scanning, they systematically profile both the steady-state membrane expression and the response to small-molecule correctors in 232 CFTR variants expressed in human cells. Crucially, they interrogate how the presence or absence of calnexin modulates these phenotypes, thereby clarifying the chaperone's role in both proteostasis and drug responsiveness at an unprecedented scale.

Methods and Experimental Design Insights

The research team designed a high-throughput platform to express a comprehensive panel of CFTR missense and in-frame deletion variants, spanning multiple functional domains. Key elements of their approach included:

• CRISPR-mediated knockout of CANX in human cell lines to generate calnexin-deficient backgrounds.
• Quantitative flow cytometry to measure plasma membrane expression of CFTR variants using epitope-tagged constructs.
• Pharmacological rescue experiments using type III correctors (notably VX-445) to assess drug responsiveness in both wild-type and calnexin-deficient cells.
• Global interactome profiling to map changes in chaperone and proteostasis factor interactions upon loss of calnexin.

This experimental framework enabled them to dissect variant- and domain-specific dependencies on calnexin for both biogenesis and corrector-mediated rescue of CFTR.

Core Findings and Why They Matter

The central discoveries from this study include:

• Calnexin is broadly required for robust CFTR plasma membrane expression, especially for variants that disrupt the second nucleotide-binding domain (NBD2) and C-terminal regions. The absence of calnexin led to substantial reductions in steady-state expression for many disease-relevant mutants.
• Pharmacological rescue by correctors is highly calnexin-dependent for variants with poor basal expression. This indicates that chaperone context in the ER can be a decisive determinant of corrector efficacy.
• Variant-specific corrector sensitivity is shaped by both the location of the mutation and its interaction with calnexin. Notably, calnexin enhanced the corrector responsiveness of mutations located in a domain-swapped region between membrane-spanning domain 2 and NBD2, particularly to the type III corrector VX-445.
• The study also shows that proteostatic effects of calnexin can be decoupled from direct changes in CFTR-mediated chloride channel activity. Thus, restoration of protein trafficking and stabilization does not always translate to functional rescue, underscoring the complexity of CFTR modulation (Tedman et al., 2025).

These findings have direct implications for the stratification of CFTR mutation 'theratypes' and highlight the necessity of considering cellular quality control context when evaluating or developing new CFTR modulators.

Comparison with Existing Internal Articles

Several recent reviews and practical guides have addressed the mechanistic basis and workflow optimization for F508del CFTR correctors. For example, the article "VX-661 and Calnexin: Unraveling CFTR Folding Rescue in Cystic Fibrosis" parallels Tedman et al.'s mechanistic focus, delving into how calnexin-driven proteostasis pathways impact the efficacy of VX-661 and similar correctors. Similarly, "VX-661 (F508del CFTR Corrector): Precision Proteostasis Modulation" discusses strategies for dissecting variant-specific rescue, echoing the reference study’s emphasis on domain and mutation context.

While these internal resources provide actionable workflows and troubleshooting guidance for deploying VX-661 in diverse cell models, Tedman et al. extend the field with a systematic, quantitative, and mutation-wide analysis that establishes a framework for predicting corrector responsiveness based on both protein domain and chaperone context. This large-scale approach informs both future experimental design and the clinical prioritization of emerging CFTR modulators.

Limitations and Transferability

Despite its comprehensive scope, several limitations should be noted:

• The study was performed in human cell lines, which, while highly informative, may not fully recapitulate the proteostasis environment of native airway or epithelial tissues.
• Pharmacological rescue was primarily tested with VX-445; while trends may translate to other correctors such as VX-661, domain- and variant-specific differences could exist (cf. internal reviews).
• Functional rescue (i.e., restoration of CFTR-mediated chloride channel activity) was not always directly assessed for every variant, highlighting the need for combined biochemical and electrophysiological validation.
• The intricate interplay between different cellular chaperones and accessory proteins remains only partially dissected, raising further questions about multi-chaperone dependencies in CFTR rescue.

Nonetheless, the deep mutational scanning strategy is readily adaptable to other quality control factors or modulator classes, offering a scalable platform for future cystic fibrosis research and drug discovery.

Protocol Parameters

• Corrector treatment (VX-661): Literature and product information recommend 3 μM VX-661 treatment for 24 hours at 26°C to promote rescue of F508del and related CFTR trafficking mutants (see product specifications).
• Calnexin modulation: For studies dissecting chaperone dependency, CRISPR-mediated knockout or siRNA silencing of CANX can be performed prior to CFTR variant expression.
• Membrane expression assessment: Quantitative flow cytometry using extracellular epitope tags is recommended to benchmark plasma membrane levels across variants.
• Pharmacological rescue assays: Include control (DMSO) and corrector-only conditions, ideally with combination potentiator (e.g., VX-770) where functional readout is required.
• Chloride channel activity: Ussing chamber or halide-sensitive YFP assays can verify restoration of CFTR-mediated chloride conductance.

Research Support Resources

For researchers seeking to implement or extend these workflows, VX-661 (F508del CFTR corrector) (SKU A2664) is available from APExBIO and can be utilized for variant-specific rescue studies or mechanistic dissection of CFTR proteostasis. The compound’s well-characterized solubility and stability profile supports robust, reproducible experiments in both basic and translational cystic fibrosis research contexts.